Clearmind Medici Stock Price, News & Analysis

Clearmind Medicine (NASDAQ: CMND) announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa trial of CMND-100, a non-hallucinogenic MEAI-based oral candidate for Alcohol Use Disorder (AUD), on November 18, 2025. The six-patient first cohort showed a favorable safety profile with no serious adverse events reported and generally good tolerability. Investigators also reported high treatment adherence, supporting feasibility and patient acceptability. Dosing was completed at Johns Hopkins and Yale under the multicenter, single- and multiple-dose protocol; the company will continue evaluation in subsequent cohorts toward a full data readout.

Clearmind Medicine (Nasdaq: CMND) filed an Israeli patent application on Nov 17, 2025 for a novel combination therapy pairing MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines such as Palmitoylethanolamide (PEA) to address depression.

The filing arises from Clearmind's collaboration with Neurothera Labs and expands a portfolio that already includes 13 patents tied to MEAI–N-Acylethanolamine combinations for conditions including alcohol use disorder, cocaine addiction, obesity and depression. Clearmind said preclinical data support MEAI's efficacy in reducing addictive behaviors while preserving normal reward pathways.

Clearmind Medicine (Nasdaq: CMND) received final approval on Nov 13, 2025 for Hadassah Medical Center in Jerusalem to join its ongoing Phase 1/2a trial of CMND-100, an oral MEAI-based candidate for Alcohol Use Disorder (AUD).

The trial is multinational and multicenter, includes Yale, Johns Hopkins and Tel Aviv Sourasky, and has completed treatment of its first cohort. The study will assess safety, tolerability, pharmacokinetics and preliminary efficacy for reducing alcohol cravings and consumption. The company expects continued patient enrollment and data collection across sites.

Clearmind Medicine (Nasdaq: CMND) announced receipt of a notice of patent publication from the China National Intellectual Property Administration dated November 12, 2025, covering its proprietary non‑hallucinogenic compound 5‑methoxy‑2‑aminoindane (MEAI) for the treatment of depression.

The release notes that preclinical studies show MEAI may enhance mood regulation and reduce anhedonia, and that the patent application expands Clearmind’s intellectual property protections for MEAI across multiple jurisdictions and for several mental health and addiction indications.

Clearmind Medicine (Nasdaq: CMND) announced completion of treatment for the first patient cohort in its ongoing FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder (AUD) on November 10, 2025. Six patients have been enrolled and treated to date, with two sites at Johns Hopkins and four at Yale, and two additional sites in Israel activated.

The multinational, multicenter single- and multiple-dose study will assess safety, tolerability, and pharmacokinetics and explore preliminary efficacy signals such as reductions in alcohol cravings and consumption among treatment-seeking and non-treatment-seeking heavy drinkers. The company highlighted the commercial context, citing a market projected to reach about $20 billion by 2032.

Clearmind Medicine (Nasdaq: CMND) received a Nasdaq Listing Qualifications notice dated November 3, 2025, for failure to meet Nasdaq Listing Rule 5550(b)(1), which requires $2,500,000 minimum stockholders' equity.

The company reported $1,065,668 of stockholders' equity as of its Form 6-K for the three and nine months ended July 31, 2025. Clearmind has 45 calendar days (until December 18, 2025) to submit a compliance plan; Nasdaq may grant up to 180 days total if the plan is accepted.

Management is evaluating options to regain compliance, including conversion of previously announced convertible promissory notes (up to $10,000,000). To date $1,045,062 of notes converted into 885,000 common shares on October 30–31, 2025, and the company expects further conversions could demonstrate compliance, though acceptance is not assured.

Clearmind Medicine (NASDAQ: CMND) filed a patent application in South Korea covering compositions of its proprietary compound 5-methoxy-2-aminoindane (MEAI) for the treatment of depression on November 5, 2025. The filing is described as strengthening Clearmind’s global IP portfolio for MEAI, a non-hallucinogenic neuroplastogen intended to modulate serotonin pathways, promote neuroplasticity, and alleviate depressive symptoms without psychedelic effects.

Preclinical studies are reported to show MEAI’s potential to enhance mood regulation and reduce anhedonia. The company says the expanded IP now includes protections across multiple jurisdictions as it prepares for further clinical development and commercialization.

Clearmind Medicine (NASDAQ: CMND) announced publication of a U.S. patent application on Oct 31, 2025 expanding intellectual property coverage for its non‑hallucinogenic neuroplastogen MEAI (5‑methoxy‑2‑aminoindane) for treatment of cocaine addiction.

The filing emphasizes MEAI's proposed mechanism—modulation of serotonin and dopamine pathways—and positions the program against a disorder with no FDA‑approved pharmacological treatments. The release cites a global market estimate of $1.36 billion in 2025 growing to $2.03 billion by 2032, and frames the application as strengthening Clearmind's IP portfolio and pipeline strategy for non‑hallucinogenic neuroplastogens.

Clearmind Medicine (Nasdaq: CMND) announced completion of treatment for the first cohort in its FDA‑approved Phase I/IIa trial of CMND‑100, an oral MEAI‑based candidate for Alcohol Use Disorder (AUD). Six patients have been enrolled and dosed so far, including two at Johns Hopkins and four at Yale; two additional sites in Israel are activated. The multinational, single‑ and multiple‑dose trial will assess safety, tolerability, and pharmacokinetics and explore preliminary efficacy signals such as reductions in alcohol cravings and consumption. The release cites a market projection rising from ~$13.2B (2024) to ~ $20B by 2032, highlighting commercial opportunity. Trial registry: NCT05913752.